Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Loading

Please wait while we load your information from QuoteMedia.

Company News

As of June 19, 2025 • 5:30 AM ET

Date/Time Source News Release
06/13/2025 07:45 AM EDT Business Wire Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics
06/12/2025 07:30 AM EDT Business Wire Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference
06/11/2025 07:30 AM EDT Business Wire Cybin to Participate in the 2025 Psychedelic Science Conference
06/03/2025 07:30 AM EDT Business Wire Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder
05/22/2025 07:30 AM EDT Business Wire Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025
05/20/2025 07:30 AM EDT Business Wire Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics
05/15/2025 07:30 AM EDT Business Wire Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder
05/14/2025 07:30 AM EDT Business Wire Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase
05/08/2025 07:30 AM EDT Business Wire Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder
05/01/2025 07:30 AM EDT Business Wire Cybin to Participate at the 28th Annual Milken Institute Global Conference
Page

Additional News

As of June 19, 2025 • 5:30 AM ET

Date/Time Source News Release
06/13/2025 09:15 AM EDT InvestorWire InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Highlights Progress on Phase 3 Psychedelic Therapeutics Program
06/12/2025 09:12 AM EDT PsychedelicNewsWire PsychedelicNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Speak at H.C. Wainwright Neuro Perspectives Conference
06/03/2025 03:01 PM EDT PRISM News Cybin Secures New U.S. Patent for DMT-Based Anxiety Treatment Program, Bolstering Phase 2 Clinical Development
06/03/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Secures U.S. Patent for CYB004 Anxiety Treatment Candidate
05/22/2025 09:05 AM EDT InvestorWire InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Discuss Phase 3 Progress and Industry Trends in May 29 Fireside Chat
05/20/2025 10:46 AM EDT SeekingAlpha Psychedelic stocks rise as FDA chief's comments seen favorable to industry
05/20/2025 09:24 AM EDT PsychedelicNewsWire PsychedelicNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Applauds FDA Support for Psychedelic Therapeutics, Advances Phase 3 Trials
05/18/2025 12:46 AM EDT Stock Traders Daily (CYBN) Investment Analysis
05/15/2025 09:45 AM EDT InvestorWire InvestorNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
05/15/2025 09:45 AM EDT InvestorWire InvestorkNewsBreaks - Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Taps Thermo Fisher for Phase 3 and Commercial Production of CYB003
Page

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.